Cassidy Disputes White House Explanation on Overton FDA Nomination
Senate Health, Education, Labor and Pensions Committee chairman Bill Cassidy (R-LA) is disputing the White House's explanation for withdrawing Heidi Overton's nomination as FDA commissioner, saying she could have won Senate confirmation and that the administration abandoned a viable path to approval.
In a statement posted on X late 11/17, Cassidy challenged the administration's contention that Overton lacked sufficient votes, calling the decision "odd" because he had been having productive discussions with committee members.
"I believe she would have had the votes to pass out of committee and pass the full Senate," Cassidy said.
According to The Hill, Cassidy suggested the final obstacle involved demands from anti-abortion Republican senators for additional assurances from the administration concerning abortion-related policies. The Administration withdrew Dr. Overton rather than make such commitments," Cassidy said.
Cassidy, who previously expressed reservations about Overton's independence, said his discussions with her had convinced him she would follow scientific evidence and challenge decisions that could endanger public health.
The comments follow FDA Webview's 11/17 report that the White House had withdrawn Overton's nomination and that outgoing Sen. Roger Marshall (R-KS), a physician who lost his reelection bid earlier this month, had emerged as a possible replacement.
No replacement nominee has been announced. FDA remains under acting commissioner Kyle Diamantas following Marty Makary's resignation in May.
Cassidy said the withdrawal and limited time remaining in the current Congress mean that confirmation of a permanent FDA commissioner will fall to Senate Democrats, who will control the chamber in the next Congress.